Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
4.020
+0.350 (9.54%)
At close: Aug 13, 2025, 4:00 PM
4.050
+0.030 (0.75%)
After-hours: Aug 13, 2025, 6:11 PM EDT
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue (ttm)
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
35.74
Revenue / Employee
119,441 EUR
Employees
118
Market Cap
521.48M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
| Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
| Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IVA News
- 2 days ago - Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 13 days ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 5 weeks ago - Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance - GlobeNewsWire
- 5 weeks ago - Inventiva receives $10 million milestone payment from CTTQ - GlobeNewsWire
- 6 weeks ago - Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease - GlobeNewsWire
- 2 months ago - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference - GlobeNewsWire
- 2 months ago - Inventiva reports 2025 First Quarter Financial Information¹ - GlobeNewsWire
- 2 months ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - GlobeNewsWire